Skip to content
Dosage GuideResearch Reference

GLP-2 Dosage

Research-based dosing protocols, timing guidance, and reconstitution reference for GLP-2. All information is for educational purposes only.

Quick Answer

In research settings, GLP-2 is typically administered via subcutaneous injection. The synthetic analog teduglutide (Gattex/Revestive) is FDA-approved for short bowel syndrome at a dose of 0.05 mg/kg daily. Research protocols using native GLP-2 often use similar weight-adjusted doses. No human clinical dose-ranging trials have been completed using native GLP-2.

→ GLP-2 Benefits→ GLP-2 Side Effects→ Full GLP-2 Profile
Table of Contents

Standard Dosage Range

Research dosing range: 0.05 mg/kg daily (teduglutide)

Educational reference only

These dosage ranges are derived from preclinical research and community protocols. No human clinical dose-ranging trials have established therapeutic doses for most research peptides. Always consult a qualified healthcare provider before starting any peptide protocol.

Dosage by Use Case

Short Bowel Syndrome

0.05 mg/kg1× daily
Duration

variable (chronic)

FDA-approved teduglutide protocol. Subcutaneous injection. Aim is to reduce parenteral nutrition dependence.

Crohn's Disease (experimental)

0.05 mg/kg1× daily
Duration

8–12 weeks

Investigational use. Subcutaneous injection. Aims to improve intestinal healing and reduce inflammation.

Chemotherapy-Induced Mucositis (experimental)

50–100 mcg/kg1× daily
Duration

2–4 weeks

Preclinical models. Subcutaneous injection. Administered during and shortly after chemotherapy cycles to protect the intestinal lining.

Intestinal Failure (experimental)

0.05 mg/kg1× daily
Duration

variable (chronic)

Investigational use. Subcutaneous injection. Goal is to improve intestinal absorption and reduce reliance on parenteral nutrition.

Timing & Frequency

Teduglutide is typically administered subcutaneously once daily, ideally at the same time each day. Consider timing around meals to optimize nutrient absorption. Native GLP-2 has a short half-life, so multiple daily injections may be required for sustained effects if using native GLP-2 instead of teduglutide.

Cycle Guidance

Teduglutide is often used chronically for conditions like short bowel syndrome. Cycling native GLP-2 may be considered, although no clear guidelines exist. Monitor for any potential side effects with prolonged use.

Reconstitution Reference

Quick reference for reconstituting GLP-2. For custom vial sizes and concentrations, use the Reconstitution Calculator.

Common Vial SizeTeduglutide is available in prefilled syringes
BAC Water VolumeN/A
Concentration & DrawN/A
StorageTeduglutide: Refrigerate at 2–8°C. Follow manufacturer's instructions.
StabilityTeduglutide: Follow manufacturer's instructions.
Use the Reconstitution Calculator → for precise injection volumes based on your exact vial size, water volume, and desired dose.

Frequently Asked Questions

What is the standard GLP-2 dosage for short bowel syndrome?
The FDA-approved teduglutide (Gattex/Revestive) dosage is 0.05 mg/kg daily via subcutaneous injection. This is the most evidence-backed protocol for this condition.
How is GLP-2 administered?
Typically via subcutaneous injection. Teduglutide is the most common form used clinically. Native GLP-2 has a very short half-life, making it less practical for clinical use.
What is the best time to inject GLP-2?
Teduglutide is usually administered once daily. Consider timing the injection around meals to potentially optimize nutrient absorption.

Last updated: 2026-02-19